



Public Meeting on Prescription Drug User Fee Act (PDUFA) Reauthorization



July 15, 2015

8:00 – 9:00 am

Registration

9:00 – 9:05 am

Welcome

Terry Toigo, Center for Drug Evaluation and Research, FDA
Meeting Moderator & Associate Director for Drug Safety Operations

9:05 – 9:15 am

Opening Remarks

Stephen Ostroff, FDA
Acting Commissioner of Food and Drugs

Robert Califf, FDA
Deputy Commissioner for Medical Products and Tobacco

9:15 – 9:30 am

PDUFA Background and Reauthorization Process

Theresa Mullin, Center for Drug Evaluation and Research, FDA
Director, Office of Strategic Programs

9:30 – 9:50 am

Panel 1 – Consumer Perspectives

Allan Coukell, Pew Charitable Trusts
Senior Director for Health Programs

Sally Greenberg, National Consumers League
Executive Director

9:50 – 10:40 am

Panel 2 – Patient Perspectives

Paul Melmeyer, National Organization for Rare Disorders
Associate Director of Public Policy

Marc Boutin, National Health Council
Chief Executive Officer

Jeff Allen, Friends of Cancer Research
Executive Director

Cynthia Bens, Alliance for Aging Research
Vice President of Public Policy

Maureen Japha, Milken Institute and FasterCures
Legal Counsel and Associate Director for IP

10:40 – 10:55 am **Break**

10:55 – 11:25 am **Panel 3 - Health Care Professionals Perspectives**
Stacie Maass, American Pharmacists Association
Senior Vice President, Pharmacy Practice and Government Affairs

James Baumberger, American Academy of Pediatrics
Assistant Director, Department of Federal Affairs

Richard J. Kovacs, American College of Cardiology
Professor of Clinical Medicine, Indiana University School of Medicine

11:25 – 11:55 am **Panel 4 – Regulated Industry Perspectives**
Sascha Haverfield, Pharmaceutical Research and Manufacturers of America
Vice President for Scientific and Regulatory Affairs

Kay Holcombe, Biotechnology Industry Organization
Senior Vice President for Science Policy

Michael Werner, Alliance for Regenerative Medicine
Partner, Holland & Knight

11:55 – 12:45 pm **Lunch**

12:45 – 1:15 pm **Panel 5 – Scientific and Academic Expert Perspectives**
Greg Daniel, Center for Health Policy, Brookings Institution
Managing Director for Evidence Development and Innovation

Daniel Carpenter, & **Aaron Kesselheim**,
Harvard University Harvard Medical School
Professor of Government *Associate Professor of Medicine*

Ernst Berndt, & **Rena Conti**,
Massachusetts Institute of Technology University of Chicago
Professor of Applied Economics *Assistant Professor of Health
Policy and Economics*

1:15 – 1:30 pm **Closing Remarks**
Janet Woodcock, Center for Drug Evaluation and Research, FDA
Center Director

1:30 – 2:00 pm **Open Public Comment**